CGTX · Cognition Therapeutics Inc · Documents
$0.79
+0.03 (+4.07%)
At close · Oct 28
Return incl. dividend (before tax)
Q4 2024 earnings call transcript
Market Cap
$72.19M
Shares
95.09M
Volume · Oct 27
324.29K
Avg daily vol (3M)
516.43K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Cognition Therapeutics aligned with FDA on a planned Phase 3 study of zervimesine in mild-to-moderate dementia with Lewy bodies, randomizing participants to 100 mg of once-daily oral zervimesine or placebo for nine months, with NPI-2 and ADCS-ADL endpoints. | 2026-10-22 | — | |
| 10-Q | — | 2026-08-07 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| 8-K | — | 2026-06-24 | — | |
| 8-K | — | 2026-06-18 | 2026-06-17 | |
| Investor Event Transcript | — | 2026-06-04 | 2026-06-30 | |
| 8-K | — | 2026-06-04 | — | |
| 8-K | — | 2026-05-21 | — | |
| 10-Q | — | 2026-05-08 | 2026-03-31 | |
| 8-K | — | 2026-05-07 | — | |
| ARS | — | 2026-04-27 | 2025-12-31 | |
| DEF 14A | — | 2026-04-27 | 2026-06-17 | |
| DEFA14A | — | 2026-04-27 | — | |
| 10-K | — | 2026-03-26 | 2025-12-31 | |
| 8-K | — | 2026-03-26 | — | |
| 8-K | — | 2026-03-02 | — | |
| 8-K | — | 2026-01-27 | — | |
| 8-K | — | 2025-12-18 | 2025-12-16 | |
| S-3 | — | 2025-12-18 | — | |
| 10-Q | — | 2025-11-06 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-09-15 | — | |
| 8-K | — | 2025-08-28 | 2025-08-27 | |
| 8-K | — | 2025-08-26 | — | |
| 8-K | — | 2025-08-07 | — | |
| 10-Q | — | 2025-08-07 | 2025-06-30 | |
| 8-K | — | 2025-06-20 | 2025-06-18 | |
| 8-K | — | 2025-06-03 | — | |
| 8-K | — | 2025-06-02 | — | |
| 8-K | — | 2025-05-08 | — | |
| 8-K | — | 2025-05-07 | — | |
| 10-Q | — | 2025-05-07 | 2025-03-31 | |
| DEF 14A | — | 2025-04-28 | 2025-06-18 | |
| ARS | — | 2025-04-28 | 2024-12-31 | |
| DEFA14A | — | 2025-04-28 | — | |
| 8-K | — | 2025-03-20 | — | |
| 10-K | — | 2025-03-20 | 2024-12-31 | |
| 8-K | — | 2025-03-12 | — | |
| 8-K | — | 2025-02-26 | — | |
| 8-K | — | 2025-01-28 | — | |
| 8-K | — | 2025-01-13 | — | |
| 8-K | — | 2024-12-18 | — | |
| 8-K | — | 2024-11-13 | — | |
| 10-Q | — | 2024-11-13 | 2024-09-30 | |
| 8-K | — | 2024-10-01 | — | |
| 8-K | — | 2024-09-13 | 2024-09-12 | |
| 8-K | — | 2024-08-28 | — | |
| 8-K | — | 2024-08-08 | — | |
| 10-Q | — | 2024-08-08 | 2024-06-30 | |
| 8-K | — | 2024-07-29 | — |
Showing 1–50 of 116 filings
Key facts
CIK
1455365
CUSIP
19243B102
13F (30d)
14 filings
14 filers
Visit website
Investor relations